Purpose of review: Cancer and cardiovascular disease are the leading causes of mortality in the USA. In this review, we highlight these shared disease pathways and provide a framework for a systems-based approach to reduce overall risk burden.
Recent findings: From traditional risk factors such as age and tobacco use to more recently recognized entities including clonal hematopoiesis, we are gaining insights into shared mechanisms. Because of these overlapping risks, providers on each level of patient care (primary care providers, cardiologists, oncologists) need to recognize and reduce these underlying risk factors. There is significant overlap in the epidemiology and risk factors for the development of cardiovascular disease and cancer, providing opportunities for joint risk factor modification.
Keywords: Cancer; Cardio-oncology; Cardiotoxicity.
An international survey of healthcare providers' knowledge of cardiac complications of cancer treatments.Cardiooncology. 2019 Sep 2;5:12. doi: 10.1186/s40959-019-0049-2. eCollection 2019. Cardiooncology. 2019. PMID: 32154018 Free PMC article.
Cardio-Oncology: A Focused Review of Anthracycline-, Human Epidermal Growth Factor Receptor 2 Inhibitor-, and Radiation-Induced Cardiotoxicity and Management.Ochsner J. 2016 Fall;16(3):250-6. Ochsner J. 2016. PMID: 27660573 Free PMC article. Review.
Shared Risk Factors for Cardiovascular Disease and Cancer: Implications for Preventive Health and Clinical Care in Oncology Patients.Can J Cardiol. 2016 Jul;32(7):900-7. doi: 10.1016/j.cjca.2016.04.008. Epub 2016 Apr 23. Can J Cardiol. 2016. PMID: 27343745 Review.
Evaluation, prevention and management of cancer therapy-induced cardiotoxicity: a contemporary approach for clinicians.Curr Opin Cardiol. 2015 Mar;30(2):197-204. doi: 10.1097/HCO.0000000000000145. Curr Opin Cardiol. 2015. PMID: 25574894
Imaging in Cardio-oncology: An Overview of an Emerging Medical Discipline.J Thorac Imaging. 2020 Jan;35(1):4-11. doi: 10.1097/RTI.0000000000000442. J Thorac Imaging. 2020. PMID: 31513052
Cited by 1 article
Cancer patients receiving immune checkpoint inhibitor therapy are at an increased risk for atherosclerotic cardiovascular disease.J Immunother Cancer. 2020 Feb;8(1):e000300. doi: 10.1136/jitc-2019-000300. J Immunother Cancer. 2020. PMID: 32034065 Free PMC article.